Stockholders’ Equity (Details) - USD ($)									3 Months Ended						9 Months Ended
	Jun. 07, 2023	May 02, 2023	Jan. 24, 2023	Jan. 23, 2023	Jan. 12, 2023	Nov. 07, 2022	Jun. 02, 2021	Jul. 01, 2020	Sep. 30, 2023	Jun. 30, 2023	Mar. 31, 2023	Sep. 30, 2022	Jun. 30, 2022	Mar. 31, 2022	Sep. 30, 2023	Sep. 30, 2022	Dec. 31, 2022	May 24, 2022	Sep. 30, 2021	Nov. 03, 2020	Oct. 08, 2020
Stockholders’ Equity [Line Items]
Stockholders received cash															$ 118,344
Common stock shares authorized (in Shares)									300,000,000						300,000,000		300,000,000
Common stock, shares, issued (in Shares)									5,674,969						5,674,969		5,604,869			300,000,000
Stockholder approval (in Shares)																				5,000,000
Preferred stock par or stated value per share (in Dollars per share)									$ 0.0001						$ 0.0001		$ 0.0001			$ 0.0001
Preferred stock, shares authorized (in Shares)									4,917,000						4,917,000		4,917,000
Stock issued during period under incentive plan, shares (in Shares)	275,000						181,818	82,397							160,498
Sale of shares (in Shares)			110,000						4,878
Stock–based compensation									$ 43,273
Stock–based compensation related to restricted stock
Exercise price (in Dollars per share)		$ 1,000		$ 1,000		$ 12.77									$ 151.8
Relative rights, percentage		7.00%													7.00%
Stock issued during period shares (in Shares)		800		800
Preferred stock redemption price per share (in Dollars per share)		$ 0.0001			$ 1,000
Purchase price		$ 800,000		$ 800,000	$ 1,600,000
Stock price per share (in Dollars per share)									$ 12.77						$ 12.77			$ 0.0001
2020 Omnibus Incentive Plan [Member]
Stockholders’ Equity [Line Items]
Restricted stock units (in Shares)															106,001
HOFV 2023 Inducement Plan [Member]
Stockholders’ Equity [Line Items]
Restricted stock units (in Shares)															6,032
Minimum [Member]
Stockholders’ Equity [Line Items]
Common stock shares authorized (in Shares)																				100,000,000
Maximum [Member]
Stockholders’ Equity [Line Items]
Common stock shares authorized (in Shares)																				300,000,000
Series C Warrants [Member]
Stockholders’ Equity [Line Items]
Exercise price (in Dollars per share)						$ 12.77									$ 30.8
Series A Preferred Stock [Member]
Stockholders’ Equity [Line Items]
Relative rights, percentage					7.00%
Stock issued during period shares (in Shares)					1,600
Preferred stock redemption price per share (in Dollars per share)					$ 0.0001
Convertible preferred stock, percentage															2.00%
Series A Preferred Stock [Member] | Authorized Capital [Member]
Stockholders’ Equity [Line Items]
Preferred stock, shares authorized (in Shares)																					52,800
Equity Distribution Agreement [Member]
Stockholders’ Equity [Line Items]
Aggregate offering price																			$ 50,000,000,000,000
Restricted Stock [Member]
Stockholders’ Equity [Line Items]
Stock–based compensation												177,411			$ 140,202	$ 1,630,871
Unamortized compensation cost									$ 0						0
Restricted Stock Units [Member]
Stockholders’ Equity [Line Items]
Unamortized compensation cost									$ 1,720,679						$ 1,720,679
Restricted stock units (in Shares)															112,033
Issuance of restricted stock units per share (in Dollars per share)									$ 14.02						$ 14.02
Stock–based compensation related to restricted stock									$ 591,346			529,549			$ 1,931,924	1,618,508
Weighted average period															1 year 6 months
Phantom Share Units (PSUs) [Member]
Stockholders’ Equity [Line Items]
Stock–based compensation									148,540			$ 0			$ 448,084	$ 0
Unamortized compensation cost									$ 151,022						$ 151,022
Weighted average period															3 months 18 days
Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant (in Shares)									88,965						88,965
Price of per share (in Dollars per share)									$ 9.62						$ 9.62